Kittipos Visitsunthorn

Kittipos Visitsunthorn

Auto-generated profile, based on publicly available information

Kittipos Visitsunthorn

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PAPeter Abbink
Peter Abbink
RLRafael A. Larocca
Rafael A. Larocca
KVKittipos Visitsunthorn
Kittipos Visitsunthorn
MBMichael Boyd
Michael Boyd
RBRafael A. De La Barrera
Rafael A. De La Barrera
DBDan H. Barouch
Dan H. Barouch
Not all vaccines afford robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination.

5 March 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ARAlessandra Ricciardi
Alessandra Ricciardi
KVKittipos Visitsunthorn
Kittipos Visitsunthorn
JDJohn P. Dalton
John P. Dalton
MNMomar Ndao
Momar Ndao
Schistosomiasis is the most important human helminth infection due to its impact on public health. The clinical manifestations are chronic and significantly decrease an individual’s quality of life. Infected individuals suffer from long-term organ pathologies including fibrosis which eventually leads to organ failure. The development of a vaccine against this parasitic disease would contribute to a long-lasting decrease in disease spectrum and transmission. Our group has chosen Schistosoma mansoni (Sm) cathepsin B, a peptidase involved in parasite feeding, as a prospective vaccine candidate. Our experimental formulation consisted of recombinant Sm-cathepsin B formulated in Montanide ISA 720 VG, a squalene based adjuvant containing a mannide mono-oleate emulsifier. Parasitological burden was assessed by determining adult worm, hepatic egg, and intestinal egg numbers in each mouse. Serum was used in ELISAs to evaluate production of antigen-specific antibodies, and isolated splenocytes were stimulated with the antigen for the analysis of cytokine secretion levels. The Sm-cathepsin B and Montanide formulation conferred protection against a challenge infection by significantly reducing all forms of parasitological burdens. Worm burden, hepatic egg burden and intestinal egg burden were decreased by 60 %, 62 %, and 56 %, respectively in immunized animals compared to controls (P = 0.0002, P < 0.0001, P = 0.0009, respectively). Immunizations with the vaccine elicited robust production of Sm-cathepsin B specific antibodies (endpoint titers = 122,880). Both antigen-specific IgG1 and IgG2c titers were observed, with the former having more elevated titers. Furthermore, splenocytes isolated from the immunized animals, compared to control animals, secreted higher levels of key Th1 cytokines, IFN-γ, IL-12, and TNF-α, as well as the Th2 cytokines IL-5 and IL-4 when stimulated with recombinant Sm-cathepsin B. The Th17 cytokine IL-17, the chemokine CCL5, and the growth factor GM-CSF were also significantly increased in the immunized animals compared to the controls. The formulation tested in this study was able to significantly reduce all forms of parasite burden, stimulate robust production of antigen-specific antibodies, and induce a mixed Th1/Th2 response. These results highlight the potential of Sm-cathepsin B/Montanide ISA 720 VG as a vaccine candidate against schistosomiasis.

25 July 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ARAlessandra Ricciardi
Alessandra Ricciardi
NZNicholas H. Zelt
Nicholas H. Zelt
KVKittipos Visitsunthorn
Kittipos Visitsunthorn
JDJohn P. Dalton
John P. Dalton
MNMomar Ndao
Momar Ndao
A vaccine against schistosomiasis would contribute to a long-lasting decrease in disease spectrum and transmission. Our previous protection studies in mice using Schistosoma mansoni Cathepsin B (Sm-Cathepsin B) resulted in 59 and 60% worm burden reduction with CpG oligodeoxynucleotides and Montanide ISA720 VG as adjuvants, respectively. While both formulations resulted in significant protection in a mouse model of schistosomiasis, the elicited immune responses differed. Therefore, in this study, we aimed to decipher the mechanisms involved in Sm-Cathepsin B vaccine-mediated protection. We performed in vitro killing assays using schistosomula stage parasites as targets for lung-derived leukocytes and serum obtained from mice immunized with Sm-Cathepsin B adjuvanted with either Montanide ISA 720 VG or CpG and from non-vaccinated controls. Lung cells and immune sera from the Sm-Cathepsin B + Montanide group induced the highest killing (63%) suggesting the importance of antibodies in cell-mediated parasite killing. By contrast, incubation with lung cells from Sm-Cathepsin B + CpG immunized animals induced significant parasite killing (53%) independent of the addition of immune serum. Significant parasite killing was also observed in the animals immunized with Sm-Cathepsin B alone (41%). For the Sm-Cathepsin B + Montanide group, the high level killing effect was lost after the depletion of CD4+ T cells or natural killer (NK) cells from the lung cell preparation. For the Sm-Cathepsin B + CpG group, high parasite killing was lost after CD8+ T cell depletion, and a reduction to 39% was observed upon depletion of NK cells. Finally, the parasite killing in the Sm-Cathepsin B alone group was lost after the depletion of CD4+ T cells. Our results demonstrate how the different Sm-Cathepsin B formulations influence the immune mechanisms involved in parasite killing and protection against schistosomiasis.

1 January 2017 in Asian Pacific Journal of Allergy and Immunology
Verified
Journal Article
Open access
NVNualanong Visitsunthorn
Nualanong Visitsunthorn
WCWanwipa Chaimongkol
Wanwipa Chaimongkol
KVKittipos Visitsunthorn
Kittipos Visitsunthorn
PPPunchama Pacharn
Punchama Pacharn
OJOrathai Jirapongsananuruk
Orathai Jirapongsananuruk
Flooding may affect aeroallergen sensitization. To evaluate aeroallergen sensitization in children with asthma and/or allergic rhinitis (AR) by skin prick test (SPT) before and after the great flood of 2011 in Bangkok, Thailand. The study was performed retrospectively in asthma and/or AR children (aged 0-18 years) in Siriraj Hospital, Bangkok, Thailand from 2009 to 2013. All of the cases received SPT with common aeroallergens. SPTs were performed from 2009-2013 in a total of 2,010 asthma and/or AR children and 58.2% and 60.5% showed positive results, respectively. Poly-sensitization to aeroallergens was found in 67.5% of asthma and 67.0% of AR SPT-positive patients. In the study period, Dermatophagoides pteronyssinus (Dp) and Dermatophagoides ferinae (Df) were the most common causes of aeroallergen sensitization (82.4% and 76.5%, respectively), followed by American cockroach (43.5%). After the severe flood in Bangkok in 2011, the trend of sensitization to American cockroach, Bermuda grass, Johnson grass, and Cladosporium spp. significantly decreased. However, the trend of sensitization to dog and Alterneria allergens in 2010 studied cases, significantly increased. During the study period, mean wheal diameter (MWD) of dog SPT was significantly associated with asthma severity, while the MWD of Dp SPT was significantly associated with AR severity. The aeroallergen sensitizations patterns had changed from previous years compared to the year during or after the flood. Thus, the great flood may have had a major impact on types of sensitization and the clinical patterns of airway allergy. Further confirmed by a prospective study is warranted.

14 June 2017 in Pediatric Emergency Care
Verified
Journal Article
Closed access
PDF file
NVNualanong Visitsunthorn
Nualanong Visitsunthorn
TKTeera Kijmassuwan
Teera Kijmassuwan
KVKittipos Visitsunthorn
Kittipos Visitsunthorn
PPPanchama Pacharn
Panchama Pacharn
OJOrathai Jirapongsananuruk
Orathai Jirapongsananuruk
Objective: The purpose of this study was to evaluate the clinical characteristics of allergy to stings from the Hymenoptera order of insects in a hospital in Thailand. Methods: A descriptive retrospective analytical study was carried out in inpatients and outpatients suffering from Hymenoptera stings from 2009 to 2013 in Siriraj Hospital. Results: Medical records of 386 patients with an allergy to Hymenoptera stings were evaluated. Anaphylaxis was more common in patients younger than 15 years, who comprised 22.3% of patients in this study. The most common sting type was from wasps (58.3%). Eighty-five percent of patients sought medical treatment less than 24 hours after being stung. A systemic reaction and anaphylaxis were found in 9.9% and 4.4% of subjects, respectively. In 17 patients with anaphylaxis, only 11 patients (64.7%) received an epinephrine (adrenaline) injection as treatment, and only 8 (47.1%) received epinephrine autoinjectors or epinephrine-prefilled syringes to prevent a possible subsequent severe reaction. Significantly more patients younger than 15 years received epinephrine for prevention of an allergic reaction than did those older than 15 years (87.5% vs 11.7%, P < 0.001). Antibiotics were given to 43.0% of patients. Conclusions: Anaphylaxis from Hymenoptera stings was more common in children than in adults. Only half of the patients visited the emergency room within 1 hour of being stung. Overuse of antibiotics and underuse of epinephrine were found. More information about Hymenoptera stings should be provided to the public, and the use of epinephrine should be encouraged in the case of severe reactions and anaphylaxis.

1 January 2017 in Asian Pacific Journal of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
NVNualanong Visitsunthorn
Nualanong Visitsunthorn
KVKittipos Visitsunthorn
Kittipos Visitsunthorn
PPPunchama Pacharn
Punchama Pacharn
OJOrathai Jirapongsananuruk
Orathai Jirapongsananuruk
CBChaweewan Bunnag
Chaweewan Bunnag
Comparison of the efficacy and safety of pollen allergen extracts using skin prick testing and serum specific IgE as references